October 17, 2024
My last night’s quote, “New highs and I say BYE as news of advanced trial is empty in the barrel.”
Breaking News:Sage Therapeutics (SAGE) initiates a “strategic reorganization” (cuts 165 or 33% of employees and approximately 55% of the R&D workforce including changes to the leadership team) to support the ongoing launch of ZURZUVAE in postpartum depression and focus pipeline development efforts ahead of a clinical study readout for dalzanemdor in Huntington’s Disease expected later this year. SAGE expects a non-recurring charge of approximately $26 M to $28 M associated with the reorganization, primarily incurred in Q4/24.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Never leave an investor uninform
October 17, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included
5 to report ... so far:
Sage Therapeutics (SAGE) 10/29 Tuesday
MiMedx (MDXG), Blueprint Medicine (BPMC) 10/30 Wednesday
Alnylam Pharmaceuticals (ALNY) 10/31 Thursday
Moderna (MRNA) 11/7 Thursday
October 17, 2024
As I wrote, “New highs and I say BYE as news of cutbacks and earnings season release’ dates
Trader angst centers on a bunch of unknowns: The focus on interest rates, geopolitical tensions, the upcoming US presidential election and Q3 earnings reports.
Be portfolio patient, as usual earnings season effect share pricing
Never leave an investor uninformed!
October 17, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included 5 to report ... so far: Sage Therapeutics (SAGE) 10/29 Tuesday MiMedx (MDXG), Blueprint Medicine (BPMC) 10/30 Wednesday Alnylam Pharmaceuticals (ALNY) 10/31 Thursday Moderna (MRNA) 11/7 Thursday
October 3, 2024
Called “Monetization Financing with DRI Healthcare Trust” as access to capital markets is shaky EDIT sold certain future license fees and other payments owed under its Cas9 license agreement with Vertex Pharmaceuticals (VRTX)to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million. EDIT closed down -$0.02 with only a +$0.06 or +1.87% aftermarket indication
September 10, 2024
Priced at $43.50 of 11.5 M shares IONS closed up +$1.44 or +3.07 M to $48.03 with a negative -$5.94 to $42.39 on Tuesday Check-out debt versus cash (below) Morgan Stanley and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering
5 hours 12 min ago
RegMed Investors (RMi) Closing Bell: sector was sold into highs
13 hours 24 min ago
RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes
14 hours 15 min ago
RegMed Investors’ (RMi) pre-open: more inflation economic data, watch your portfolio’s 6
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
